Table 1. Subject Characteristics.
Characteristic | Bivalirudin | Heparin | P value |
(n = 8) | (n = 8) | ||
Clinical Characteristics | |||
Age (years) | 59.8±12.2 | 62.8±11.2 | 0.6 |
Sex (% men) | 87.5 | 87.5 | 0.5 |
Race (% Caucasian) | 87.5 | 100 | 0.2 |
Height (cm) | 174.7±10 | 173.8±12.4 | 0.9 |
Weight (kg) | 90±13.4 | 101.7±21.8 | 0.2 |
BSA (m2) | 2.1±0.2 | 2.1±0.3 | 0.4 |
BMI | 29.5±4.5 | 3.9±7.8 | 0.3 |
Past Medical History (%) | |||
Hypertension | 87.5 | 87.5 | 0.5 |
Diabetes mellitus | 12.5 | 50 | 0.1 |
Active tobacco use | 25 | 0 | 0.1 |
Coronary artery disease | 25 | 62.5 | 0.04 |
Hypercholesterolemia | 87.5 | 87.5 | 0.5 |
Myocardial infarction | 12.5 | 12.5 | 0.5 |
Cerebrovascular disease | 0 | 0 | N/A |
Peripheral vascular disease | 25 | 0 | 0.1 |
Atrial fibrillation | 0 | 12.5 | 0.2 |
Medications (%) | |||
Aspirin | 87.5 | 87.5 | 0.5 |
Clopidogrel | 87.5 | 87.5 | 0.5 |
β-blocker | 87.5 | 75 | 0.3 |
Angiotensin converting enzyme inhibitor | 12.5 | 62.5 | 0.02 |
Calcium channel blocker | 12.5 | 12.5 | 0.5 |
Angiotensin-receptor-blocker | 25 | 0 | 0.1 |
Aldosterone antagonist | 0 | 0 | N/A |
Diuretic | 0 | 0 | N/A |
Anti-lipid agent | 87.5 | 87.5 | 0.5 |
Lab Values | |||
Na+ | 139.6±2.9 | 137.9±0.8 | 0.07 |
K+ | 4.2±0.4 | 4.1±0.3 | 0.6 |
Cl- | 106.1±3.5 | 103.8±0.9 | 0.06 |
CO2 | 26±1.7 | 26.9±1.2 | 0.3 |
BUN | 14.5±3.0 | 14.6±6.6 | 0.9 |
Creatinine | 1.0±0.4 | 0.9±0.3 | 0.9 |
Glucose | 111.6±22.5 | 120.9±24.1 | 0.3 |
White blood cells | 7.4±1.7 | 8.1±2.0 | 0.6 |
Hemoglobin | 14.1±1.2 | 12.5±1.3 | 0.05 |
Platelets | 185.8±22.8 | 188.6±44.9 | 0.9 |
Prothrombin time | 12.4±0.7 | 12.8±0.7 | 0.5 |
PTT | 22.5±2.8 | 30.5±13.2 | 0.2 |
INR | 1.0±0.1 | 1.1±0.1 | 0.4 |
EF (%) | 60.2±9.9 | 52.5±8.8 | 0.4 |